TARKINAID

Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases

Coordinatore	SEMMELWEIS EGYETEM    more  Organization address address: Ulloi ut 26 city: BUDAPEST postcode: 1085 contact info Titolo: Prof. Nome: Miklós Cognome: Tóth Email: send email Telefono: +361 266 0791 Fax: +361 266 0791
Nazionalità Coordinatore	Hungary [HU]
Totale costo	3˙912˙000 €
EC contributo	2˙999˙860 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-single-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2015-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	SEMMELWEIS EGYETEM  Organization address address: Ulloi ut 26 city: BUDAPEST postcode: 1085 contact info Titolo: Prof. Nome: Miklós Cognome: Tóth Email: send email Telefono: +361 266 0791 Fax: +361 266 0791	HU (BUDAPEST)	coordinator	551˙962.00
2	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN  Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 contact info Titolo: Prof. Nome: Markus Cognome: Sperandio Email: send email Telefono: +49 89 2180 76505 Fax: +49 89 2180 76503	DE (MUENCHEN)	participant	493˙280.00
3	UNIVERSITA DEGLI STUDI DI VERONA  Organization address address: VIA DELL ARTIGLIERE 8 city: VERONA postcode: 37129 contact info Titolo: Dr. Nome: Enrico Maria Cognome: Cazzaroli Email: send email Telefono: +39 045 8126446 Fax: +39 045 8126446	IT (VERONA)	participant	296˙082.00
4	VICHEM CHEMIE KUTATO KFT  Organization address address: HERMANN OTTO UTCA 15 city: BUDAPEST postcode: 1022 contact info Titolo: Mr. Nome: Zoltán Cognome: Dobai Email: send email Telefono: +36 1 4872080	HU (BUDAPEST)	participant	296˙010.00
5	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  Organization address address: Rue Michel -Ange 3 city: PARIS postcode: 75794 contact info Titolo: Ms. Nome: Armelle Cognome: Barelli Email: send email Telefono: +33 561336080 Fax: +33 562172901	FR (PARIS)	participant	295˙950.00
6	UNIVERSIDADE FEDERAL DO RIO DE JANEIRO  Organization address address: AV BRIGADEIRO TROMPOWSKI SN 2 city: RIO DE JANEIRO postcode: 21941 590 contact info Titolo: Ms. Nome: Marta Cognome: Farias Email: send email Telefono: +5521 2562 6527 Fax: +5521 2280 8193	BR (RIO DE JANEIRO)	participant	246˙822.00
7	UNIVERSITAETSKLINIKUM FREIBURG  Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Jürgen Cognome: Dreyer Email: send email Telefono: +49 761 270 20810 Fax: +49 761 270 18890	DE (FREIBURG)	participant	246˙228.00
8	BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNASKAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS  Organization address address: ALEXANDER FLEMING STREET 34 city: VARI postcode: 16672 contact info Titolo: Dr. Nome: Piyi Cognome: Papadaki Email: send email Telefono: +30 210 9656310 Fax: +30 210 9656563	EL (VARI)	participant	177˙570.00
9	AMBIOTIS SAS  Organization address address: RUE JEANNE MARVIG 29 city: TOULOUSE postcode: 31400 contact info Titolo: Dr. Nome: Marc Cognome: Dubourdeau Email: send email Telefono: 33562244157	FR (TOULOUSE)	participant	147˙978.00
10	FUNDACAO OSWALDO CRUZ  Organization address address: AVENIDA BRASIL 4365 city: RIO DE JANEIRO postcode: 21040 900 contact info Titolo: Dr. Nome: Adolfo Horácio Cognome: Chorny Email: send email Telefono: +5521 22092252 Fax: +5521 22092644	BR (RIO DE JANEIRO)	participant	147˙978.00
11	ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU  Organization address address: VIA FIORENTINA 151 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Cristiana Cognome: Tozzi Email: send email Telefono: 390578000000 Fax: 390578000000	IT (SIENA)	participant	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant consortium have recently obtained genetic evidence showing that myeloid Src-family kinases (Hck, Fgr and Lyn) are indispensable for murine models of autoimmune inflammatory diseases such as rheumatoid arthritis or blistering skin diseases. They also developed a number of novel Src-family kinase inhibitors that also block inflammation-related in vitro leukocyte functions. The applicants will test and further develop novel Src-family kinase inhibitors as anti-inflammatory compounds, using several in vitro and in vivo inflammation assays to optimize the structure of the selected molecules. They will also test whether Src-family inhibitors already in clinical use in oncology patients also inhibit inflammatory processes. Finally, they will use Src-family kinase-deficient mice in several inflammation models to test the role of those kinases in more detail and to provide further reference information for the consortium's preclinical drug development activity. The selected inhibitors and mutant mice will be pre-screened using various inflammation-related in vitro leukocyte functions and short-term in vivo inflammation models, and then analyzed in detail using a number of in vivo mouse models of chronic autoimmune and inflammatory diseases. The project is expected to result in development of novel preclinical drug candidates against chronic autoimmune and inflammatory disease with novel mechanism of action, as well as novel knowledge on the role of Src-family kinases in inflammatory diseases. The project will be performed in close cooperation between European and Brazilian scientists.'